Safety and efficacy of 4 dosage regimens of APT-1011: Results from a phase 2b randomized double blind placebo-controlled trial to select the best dosage regimen for further development. ( NCT03191864; EudraCT Number: 2016-004749-10)

(1) University of North Carolina School of Medicine,Chapel Hill,United States


(3) Technische Universität München,München,Germany

(4) Centre Hospitalier Universitaire Vaudois,Lausanne,Switzerland

(5) Adare Pharmaceuticals,Lawrence Township,United States

(6) University of Pennsylvania Perelman School of Medicine,Philadelphia,United States

(7) Northwestern University,Chicago,United States

This item was part of the Late breaking abstracts: From eosinophilic oesophagitis to novel obesity therapies (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019